COMMUNIQUÉS West-GlobeNewswire
-
Elkedonia strengthens Board of Directors with appointment of Pierre d’Epenoux as Independent Chairman
22/04/2026 -
Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026
22/04/2026 -
Curiox Biosystems Signs Master Software License Agreement for Enterprise-Scale Pluto Code Deployment
22/04/2026 -
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
22/04/2026 -
Triple Green Farms CBD Gummies Claims Evaluated: The Best CBD Gummy Formula on the Market Under Investigation
22/04/2026 -
RNK Health NAD+ Longevity Therapy Claims Evaluated: The Clinician-Guided NAD Injections & Medication Protocol
22/04/2026 -
pHemmePure Claims Evaluated: Feminine UTI Balance Formula for Vaginal pH Support by Board-Certified Urologist
22/04/2026 -
Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS
22/04/2026 -
Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
21/04/2026 -
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
21/04/2026 -
Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026
21/04/2026 -
Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States
21/04/2026 -
TELA Bio to Announce First Quarter 2026 Financial Results
21/04/2026 -
Neuro Salt Ingredients Decoded: Deciphering the Difference Between Official Website Hype & Actual Health Benefits
21/04/2026 -
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
21/04/2026 -
Oculis Publishes Invitation to the Annual General Meeting
21/04/2026 -
OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026
21/04/2026 -
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
21/04/2026 -
Oculis Publishes Invitation to the Annual General Meeting
21/04/2026
Pages